Mylan N V 's Revenue in the fiscal year 2019 $ 11,500.50 millions
Mylan N V 's Revenue in the fiscal year 2018 $ 11,433.90 millions
Mylan N V 's Revenue in the fiscal year 2017 $ 11,907.70 millions
Mylan N V 's Revenue in the fiscal year 2016 $ 11,076.90 millions
Mylan N V 's Revenue in the fiscal year 2015 $ 9,429.30 millions
MYL Revenue third quarter 2020 Y/Y Growth Comment
Mylan N v reported Revenue growth of 0.35% year on year in the third quarter 2020, to $ 2,972.10 millions, this is lower than Mylan N V 's recent average Revenue increase of 19.76%.
Looking into third quarter 2020 results within Major Pharmaceutical Preparations industry 139 other companies have achieved higher Revenue growth. While Mylan N V ' s Revenue increase of 0.35% ranks overall at the positon no. 1951 in the third quarter 2020.
Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020
Mylan N V 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
142.17 %
4.58 %
-27.38 %
(Dec. 31. 2007)
MYL's III. Quarter Q/Q Revenue Comment
Mylan N v achieved in the III. Quarter 2020 above company average sequential Revenue increase of 8.82%, to $ 2,972.10 millions, from $2,731.20 millions in the second quarter. MYL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 146 other companies have achieved higher Revenue quarter on quarter growth. While Mylan N V 's Revenue growth quarter on quarter, overall rank is 2404.
Mylan N v achieved in the III. Quarter 2020 above company average sequential Revenue increase of 8.82%, to $ 2,972.10 millions, from $2,731.20 millions in the second quarter. MYL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 146 other companies have achieved higher Revenue quarter on quarter growth. While Mylan N V 's Revenue growth quarter on quarter, overall rank is 2404.
Mylan N V 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2020)
12 Months Ending (Jun 30 2020)
12 Months Ending (Mar 31 2020)
12 Months Ending (Dec 31 2019)
12 Months Ending (Sep 30 2019)
Cumulative Revenue 12 Months Ending
$ 11,514.30
$ 11,503.90
$ 11,624.20
$ 11,500.50
$ 11,387.40
Y / Y Revenue Growth (TTM)
1.11 %
1.91 %
3.37 %
0.58 %
-1.78 %
Year on Year Revenue Growth Overall
Ranking
# 2051
# 0
# 0
# 0
# 2029
Seqeuential Revenue Change (TTM)
0.09 %
-1.03 %
1.08 %
0.99 %
0.88 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1641
# 1945
# 0
# 0
# 0
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2020 period, Mylan N V 's cumulative twelve months Revenue were $ 11,514 millions, company would post below average annual Revenue growth of 0.88% year on year, if the fiscal year would end at Sep 30 2020. A slow-down in the Mylan N V 's Revenue growth from the 2731.2% growth in Jun 30 2020.
In the Healthcare sector 353 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2051.
With the quarterly Revenue reported in the Sep 30 2020 period, Mylan N V 's cumulative twelve months Revenue were $ 11,514 millions, company would post below average annual Revenue growth of -7.55% year on year, if the fiscal year would end at Sep 30 2020. A slow-down in the Mylan N V 's Revenue growth from the 2731.2% growth in Jun 30 2020.
In the Healthcare sector 353 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2051.
About Mylan N V Revenue Growth Rates (MYL), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.61%